Page last updated: 2024-11-13
delta4-dafachronic acid
Description
delta4-dafachronic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Delta(4)-dafachronic acid : A cholestanoid that is cholest-4-en-26-oic acid which is substituted at position 3 by an oxo group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 22216313 |
| CHEBI ID | 78686 |
| SCHEMBL ID | 1176929 |
| MeSH ID | M0527819 |
Synonyms (17)
| Synonym |
|---|
| 3-oxocholest-4-en-26-oic acid |
| delta(4)-dafachronic acid |
| SCHEMBL1176929 |
| 3-keto-4-cholestene-27-oic acid |
| cholest-4-en-3-one-26-oic acid |
| 3-keto-4-cholestene-26-oic acid |
| CHEBI:78686 |
| cholest-4-en-3-one-27-oic acid |
| 23017-97-2 |
| cholest-4-en-26-oic acid, 3-oxo- |
| 3-oxocholest-4-en-26-oic acid # |
| PSXQJZDFWDKBIP-NNWQCNCGSA-N |
| delta4-dafachronic acid |
| .delta.4-dafachronic acid |
| Q27147911 |
| (6r)-6-[(8s,9s,10r,13r,14s,17r)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-methylheptanoic acid |
| DTXSID501347054 |
Drug Classes (3)
| Class | Description |
|---|
| 3-oxo-Delta(4) steroid | A 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position. |
| dafachronic acids | Any of a family of steroid acids derived from sterols by oxidation with a cytochrome p450 that bind and activate the orphan nuclear receptor DAF-12 in the nematode Caenorhabditis elegans. Note that the singular term 'dafachronic acid' has been used as a synonym for the (non-natural) fully saturated (5alpha,25S)-3-oxocholestan-26-oic acid. |
| C27-steroid | A steroid compound with a structure based on a 27-carbon (cholestane) skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.26
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 13.26 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 5.21 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |